Skip to content

Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans

Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05368987
Enrollment
250
Registered
2022-05-10
Start date
2022-02-01
Completion date
2028-09-30
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Brief summary

This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include preliminary screenings, baseline visits, and experimental visits across four days

Detailed description

The experiments proposed are aimed to understand how timing and location of transcranial magnetic stimulation (TMS) in humans will impact their ability to reduce conditioned fear responses and impact the activation of their brain regions involved in fear regulation. The researchers will use a novel TMS approach to vary timing and location of its delivery so that the researchers can characterize and establish best time and location to obtain optimal impact on fear inhibition, and then test these parameters in PTSD patients and see if such can rescue extinction deficits in PTSD. The anticipated impact is to enhance our understanding of the neural mechanisms of associated with TMS use and explore potential novel approaches for advancing PTSD treatment.

Interventions

DEVICETranscranial magnetic stimulation (TMS)

Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.

BEHAVIORALFear Conditioning and Extinction Paradigm

Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day. On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner. On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Willing and able to provide informed consent. * Inclusion Criteria for PTSD Subjects - Diagnosis of current PTSD * Inclusion Criteria: Healthy Controls (HC) - no current psychiatric disorders ("Axis I" disorders)

Exclusion criteria

* Lifetime history of seizure or significant head trauma or other significant neurologic disease (e.g., tic disorder) * History of serious/significant psychiatric diagnoses ("Axis I" diagnoses) * Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS and clinical judgment or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily * Use of neuroleptics within one year prior to study * Current substance use * Pregnancy (to be ruled out by urine β-HCG). * Metallic implants or devices contraindicating magnetic resonance imaging. * Currently taking medications that lower the seizure threshold. These include antipsychotics, high dose theophylline or stimulants such as methylphenidate. Patients taking bupropion must be on a stable dose (\*last 3 months) and take less than or equal to 300 mg/day. * Implanted devices in subject's head (shunts, cochlear implants); metal in subject's head (other than dental implants). * High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or the informed consent process * Additional

Design outcomes

Primary

MeasureTime frameDescription
Skin Conductance Response (SCR)Experimental Day 1Conductance is measured by placing two electrodes next to the skin and passing a tiny electric charge between the two points. SCR is proportionally related to the number of sweat glands that are activated, meaning in essence that the more emotionally aroused an individual is, the more the SCR amount is increased.
Functional MRI (fMRI) blood-oxygen-level-dependent (BOLD) responsesExperimental Day 1fMRI data, including blood-oxygen-level-dependent (BOLD) responses, is used in neuroimaging studies assess neural correlate activations and observe the increase/decrease in activation of a particular brain area in response to a specific cue. When these cells are active, there is an increase in blood oxygen in the surrounding area.

Secondary

MeasureTime frameDescription
Score on State-Trait Anxiety Inventory (STAI) - Form Y1Experimental Day 1STAI - Form Y1 is a commonly used measure of trait and state anxiety that consists of 20 statements that describe oneself. Each statement is scored from 1 (Not at all) to 4 (very much so). The total score range is 20-80. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80).

Countries

United States

Contacts

CONTACTMohammed Milad, PhD
Mohammed.R.Milad@uth.tmc.edu713-486-2754
PRINCIPAL_INVESTIGATORMohammed Milad, PhD

The University of Texas Health Science Center at Houston (UTHealth Houston)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026